Additionally, taken the theatrical role of PTPN2 and CD8+ T cells in MASH pathogenesis, therapeutic targeting of PTPN2 might importantly enhance outcomes for patients with MASLD as well as MASH. Here, CD8A is linked to metabolic dysfunction-associated steatohepatitis.